What is Invivyd, Inc.'s market cap?

Invivyd, Inc. (IVVD) has a market capitalization of $179.7M and trades on NASDAQ.

Who are Invivyd, Inc.'s competitors?

Invivyd, Inc.'s key competitors include Gilead Sciences, Moderna, Merck & Co., and others. These companies compete in similar markets and product categories.

Who does Invivyd, Inc. partner with?

Invivyd, Inc.'s notable partners include Adimab, LLC, WuXi Biologics, Population Health Partners, and others.

Where is Invivyd, Inc. headquartered?

Invivyd, Inc. is headquartered in United States of America and employs approximately 95 people. It has been publicly traded since 2021.

Invivyd, Inc.

IVVD

Invivyd, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for serious viral infectious diseases.

Market cap

$179.68M+99.2%

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$13.7MMiss by $4.3M EPS-$0.13Miss by $0.05

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$14.4M

EPS estimate-$0.15

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Gilead Sciences$162.05B+15.3%

Pfizer$140.61B+1.7%

Moderna$22.1B+68.3%

Vir Biotechnology, Inc.$1.5B+95.9%

Novavax$1.2B+4.5%

Enanta Pharmaceuticals$370.2M+116%

Invivyd, Inc.$179.7M+78.9%

By revenue growth

Vir Biotechnology, Inc.+214%

By net margin

Gilead Sciences30.99%+10.2pp

Pfizer15.65%+6.3pp

Merck & Co.13.59%-13.7pp

Novavax-14.73%-52.9pp

Moderna-143.55%-37.9pp

Vir Biotechnology, Inc.-675.96%+2,093pp

Profile

Invivyd, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for serious viral infectious diseases. The company leverages a proprietary integrated technology platform and viral surveillance to engineer antibodies designed to maintain efficacy against evolving viral variants. Its primary focus is providing protection for immunocompromised individuals who do not respond adequately to traditional vaccinations.

Competitive position

Invivyd is a pioneer in developing mAbs specifically for the immunocompromised population in the COVID-19 era, holding the only current EUA for a mAb in pre-exposure prophylaxis.

GeographiesUnited States, Australia

Customer segmentsImmunocompromised individuals, Specialty pharmaceutical distributors, Healthcare providers

Business modelR&D-driven drug development, Commercial-stage biopharma

SuppliersAntibody discovery platforms, Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), Viral surveillance data

CustomersSpecialty distributors, Hospitals and oncology clinics, Infusion centers, Government health programs

CountryUnited States of America

Listed2021

Employees95.0

CEOWilliam E. Duke Jr.

SectorHealthcare

IndustryBiotechnology

Websiteinvivyd.com

FilingsSEC EDGAR

Questions, answered.

What is Invivyd, Inc.'s market cap?: Invivyd, Inc. (IVVD) has a market capitalization of $179.7M and trades on NASDAQ.
Who are Invivyd, Inc.'s competitors?: Invivyd, Inc.'s key competitors include Gilead Sciences, Moderna, Merck & Co., and others. These companies compete in similar markets and product categories.
Who does Invivyd, Inc. partner with?: Invivyd, Inc.'s notable partners include Adimab, LLC, WuXi Biologics, Population Health Partners, and others.
Where is Invivyd, Inc. headquartered?: Invivyd, Inc. is headquartered in United States of America and employs approximately 95 people. It has been publicly traded since 2021.